VYNE Therapeutics announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. Dr. Borowski has served as Vice President at Access Biotechnology, a leading healthcare investor, since January 2022, and previously served as Senior Associate beginning in July 2019.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VYNE:
- VYNE Therapeutics files to sell 39.27M shares of common stock for holders
- VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- VYNE Therapeutics expects cash to fund operations through 2025
- VYNE Therapeutics reports Q3 EPS (201) vs. ($2.94) last year
- VYNE Therapeutics to host virtual research and development day
